| Autor: |
GOGICHAISHVILI, LEVAN, LOBZHANIDZE, GIA, SCHLIT, HANS J., BEDINASHVILI, ZANDA, SHARVADZE, LALI, GOISHVILI, NANA, JANGAVADZE, MIKHEIL |
| Předmět: |
|
| Zdroj: |
World Academy of Sciences Journal; Jan/Feb2024, Vol. 6 Issue 1, p1-6, 6p |
| Abstrakt: |
The early diagnosis of hepatocellular carcinoma (HCC) and the detection of disease recurrence are vital for the improvement of patient survival. The aim of the present study was to investigate the use of circulating plasma gankyrin mRNA expression as a potential biomarker for patient management. A total of 64 patients and healthy volunteers were recruited in the present study [54 individuals and 10 archived material of formalin-fixed paraffin-embedded samples (5 normal liver samples were obtained from transplant donors and 5 from patients undergoing cirrhotic liver biopsy)]. The blood plasma of patients with HCC (n=32), metastatic HCC (n=5), cirrhosis (n=7), hepatitis C virus+ (HCV+; n=5) and healthy individuals (n=5) was evaluated. The expression levels of gankyrin/PSMD10 mRNA in tissue samples from patients with HCC (tumor and adjacent; n=32), cirrhosis (n=5) and normal liver (n=5) were evaluated. RNA extraction from peripheral blood and formalin-fixed paraffin-embedded tissue samples and reverse-transcription-quantitative polymerase chain reaction were performed using commercially available kits according to standard procedures. The relative expression levels were calculated using the 2-ΔΔCq method. In patients with cirrhosis, HCV+ and healthy individuals, gankyrin/PSMD10 RNA was not determined. In all patients with either HCC or metastatic HCC, target RNA was detected. The mean gankyrin/PSMD10 expression in tissues exhibited significant differences between groups. Evidence was provided that gankyrin RNA expression was significantly increased in HCC compared with that in normal and cirrhotic tissues. Gankyrin RNA was not detectable in the blood plasma of healthy individuals and individuals without cancer, while its expression was significantly increased in the plasma of patients with HCC. Gankyrin RNA in liquid biopsy can thus be used for screening patients who belong to the risk groups for the development of HCC. Since gankyrin is not specific for HCC, it needs to be used with other markers for the diagnosis of HCC, although it can be used alone for the early detection of tumor recurrence. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
